As impaired CRBN-CRL4 E3 ligase activity due to mutation, deletion or downregulation leads to altered IMiD-sensitivity in multiple myeloma cell lines and patients9–11, we examined its status in the five patients included in our proteomic analyses. This evidence concerns the gene CRBN and plasma cell myeloma.